Hematology

AYA

Questions discussed in this category

How do you monitor risk of erythrocytosis from testosterone use for female to male transgender patients?

1 Answer available

How do you manage severe hypertriglyceridemia in the adolescent & young adult population receiving chemotherapy for ALL, in the absence of complications related to hypertriglyceridemia?

1 Answer available

How would you treat a patient with Hodgkin lymphoma who has an isolated relapse within the CNS?

2 Answers available

How do you mitigate 6-MP-induced GI toxicity in pediatric and AYA patients with leukemia?

2 Answers available

For T cell ALL treated in CR (without transplant), how often do you do BM biopsies as part of surveillance, and for how long?

What would you want community oncologists to know when following these patients? Are there any other special issues to follow especially in AYA?

1 Answer available

Would you recommend adding a TKI to a pediatric regimen for a AYA B-ALL patient with IKZF1 mutation?

1 Answer available

Would you consider using DOACs in a young patient with SLE and Libman-Sacks endocarditis, who is negative for APS?

2 Answers available

What are your recommendations for a male patient who was recently started on imatinib and wants to conceive?

4 Answers available

What is the benefit of cytoreduction with Hydroxyurea for patients with newly diagnosed chronic phase CML with a WBC count >100 prior to the initiation of a TKI?

1 Answer available

Which, if any, young/fit intermediate-risk AML patients would you not offer allogeneic transplant to in MRD- CR1?

1 Answer available

What criteria is needed in relapsed/refractory B-cell ALL to choose CAR-T therapy over conventional stem cell transplant as destination therapy?

1 Answer available

Is there any benefit to transplant patients with Ph+ ALL who have achieved MRD-negativity?

1 Answer available

What is your approach to pediatric or AYA patients with B-cell ALL who relapse after CD-19 CAR-T?

1 Answer available

Under what circumstances would you consider anticoagulation in a young female patient with persistently elevated factor XI activity?

While this is a known risk factor for venous [Meijers et al NEJM 2000] and potentially arterial [Yang et al, Am J Clin Pathol 2006] thrombosis, it is ...

1 Answer available

What strategies have you found to be most effective in engaging PCPs in a primary-care or shared-care model of survivorship for pediatric and AYA patients who will receive ongoing care in their communities away from their primary oncology treatment site?

In follow up to @Jacqueline Casillas presentation at ASCO 2021 regarding models of survivorship care delivery for AYA patients.

1 Answer available

What additional testing, if any, should be performed for an adolescent patient with heavy menstrual bleeding and a negative von Willebrand disease evaluation?

1 Answer available

How would you approach treatment in an otherwise young, fit patient with transformed AML currently in remission with a plan for transplant and was found to have an invasive fungal infection not amenable to resection upon recovery from induction?

Would you consider “bridging” therapy with something like an HMA?

1 Answer available

What are the options of induction treatment of young AML patients who are on CRRT, continuous renal replacement therapy ?

1 Answer available

For pre-menopausal female patients who present with acute leukemia in need of urgent anti-neoplastic therapy, what is your preferred approach in effort to preserve fertility?

Does acute leukemia sub-type affect your decision?

1 Answer available

Would you recommend prophylactic cranial irradiation (PCI) for a teenager with a T cell acute lymphoblastic leukemia in remission?

If so, what dose would you recommend?

1 Answer available

How do you determine whether to treat a young adult with stage IA Hodgkin Lymphoma with the adult or pediatric treatment paradigm?

At what age would you treat an early stage hodgkins lymphoma patient with ABVD + RT (adult treatment) vs OEPA x 2 or AV-PC x 3 (pediatric paradigm)?&n...

2 Answers available

Do you have preferred regimens for young patients (<30 y/o) with early stage DLBCL?

Guidelines indicate RCHOPx3 +RT as category I and RCHOP x 6 below that; long term f/u for SWOG 8736 showed similar PFS and OS. Do you have and approac...

1 Answer available

Papers discussed in this category

Fertil. Steril., 2013 Sep 05

Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-09-01

Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.

Blood,

R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.

J. Clin. Oncol., 2019 Sep 10

Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-07-01

Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-03-20

Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy.

J. Clin. Oncol.,

Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.

Haematologica, 2019 Oct 17

Bleeding disorders in adolescents with heavy menstrual bleeding in a multicenter prospective US cohort.

J Thromb Haemost,

Standardizing care to manage bleeding disorders in adolescents with heavy menses-A joint project from the ISTH pediatric/neonatal and women's health SSCs.

Blood, 2008-02-15

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).

Blood, 2016-07-28

Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Blood advances, 2016-12-27

US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.

The Lancet. Haematology, 2018-12

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.

N Engl J Med,

Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.

J Clin Oncol, 2021 Dec 9

Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.

Blood Cancer Discov, 2021 Dec 01

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-11-01

Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.

Blood, 2018 Apr 5

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.

Blood Adv, 2021 Aug 24

Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.

Blood, 2014 Apr 16

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.

J Clin Oncol, 2018 Mar 02

IKZF1 Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.

N Engl J Med, 2009 Jan 07

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.

Front Oncol, 2020 Jul 16

Use of Allopurinol to Mitigate 6-Mercaptopurine Associated Gastrointestinal Toxicity in Acute Lymphoblastic Leukemia.

Leukemia, 2021 Jun 26

DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis.

Haematologica, 2021 Nov 01

Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia.

American journal of hematology, 2016-09

Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.

Blood, 2017 Jun 13

How I treat patients with aggressive lymphoma at high risk of CNS relapse.

Related Topics in Hematology